Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypophosphatasia and Ectopic Calcification Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALPL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALPL ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation essential for enzymatic activity. | View ALPL Products |
| Gene Delivery | ALPL Lentivirus Particles. Full-length ORF with GPI-anchor for stable cell line construction. For cell-based activity assays. | View ALPL Products |
| Benchmark Ab | Anti-ALPL Reference Antibody (Inhibitory Class). Recombinant positive control for binding and activity inhibition assays. | View ALPL Products |
| Validator | ALPL siRNA Set. For knockdown verification and specificity controls in cellular assays. | View ALPL Products |
| Related Target ENPP1 | ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1). Regulates PPi levels antagonistically to ALPL; critical for mineralization balance studies. | View ENPP1 Products |
| Related Target ALPI | ALPI (Alkaline Phosphatase, Intestinal). Isoform specificity control; essential for selectivity screening against non-target ALP isoforms. | View ALPI Products |
| Related Target ABCC6 | ABCC6 (ATP Binding Cassette Subfamily C Member 6). Upstream regulator of PPi metabolism; mutations cause PXE; relevant for ectopic calcification models. | View ABCC6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Metal-cofactor dependent activity preservation (Zn²⁺/Mg²⁺) | HEK293 expressed proteins with native glycosylation; >95% purity by SDS-PAGE; Theoretical MW confirmed by mass spectrometry |
| Isoform selectivity (ALPL vs ALPI vs ALPP) | Strictly verified sequences with unique C-terminal regions; homolog panel proteins available for counter-screening |
| Cross-species toxicology evaluation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins with >95% purity; sequence verified for epitope conservation |
| False positives in inhibition assays | Validated siRNA included for specificity checks; endotoxin controlled (<1 EU/µg) to prevent artifactual enzyme inhibition |
Live ALPL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALPL therapeutics is bifurcating between enzyme replacement optimization for rare disease (Hypophosphatasia, HPP) and small molecule inhibition for common indications (vascular calcification, chronic kidney disease-mineral and bone disorder, PXE, GACI). As first-generation biologics (Asfotase alfa) establish the market, the next wave of R&D is targeting oral bioavailability and isoform-selective inhibitors to manage chronic ectopic calcification without affecting bone health. This dual-track strategy also includes next-generation ERT with improved half-life and bone-targeting, and gene therapy approaches for severe HPP.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement | Alexion/AstraZeneca, Mereo Biopharma | Hypophosphatasia (Pediatric/Adult) | Activity preservation assays (Need HEK293-expressed ALPL with native glycosylation) |
| Small Molecule Inhibitor | Arthex Biotech, Inozyme Pharma (combination) | Vascular Calcification, CKD-MBD, PXE | Isoform selectivity panel (Need ALPL vs ALPI vs ALPP proteins) |
| Monoclonal Antibody (Inhibitory) | Preclinical/Biotech | Ectopic Calcification | Heterodimer disruption assays; pH-dependent binding (Need high-purity ECD-Fc) |
| Gene Therapy | Ultragenyx, Beam Therapeutics | Severe Hypophosphatasia | Expression validation (Need Lentivirus for stable cell lines) |
Key Scientific Considerations & Assay Strategies
ALPL (TNAP) is a GPI-anchored homodimeric metalloenzyme requiring Zn²⁺ (2 per subunit) and Mg²⁺ (1 per subunit) for catalytic activity. Its primary function is to hydrolyze pyrophosphate (PPi), a potent inhibitor of mineralization. When developing inhibitors for ectopic calcification or ERT for HPP, several critical assay needs must be addressed:
- Metal ion dependency: Recombinant ALPL must be expressed in HEK293 cells to ensure proper metal binding and glycosylation; bacterial expression yields inactive protein.
- Subfamily counter-screening: Human alkaline phosphatases include ALPL (tissue-nonspecific), ALPI (intestinal), ALPP (placental), and ALPG (germ cell). Inhibitors must show >100-fold selectivity for ALPL to avoid gastrointestinal and reproductive toxicity.
- Bone-targeting for ERT: Asfotase alfa uses a deca-aspartate (D10) tag for hydroxyapatite binding. Assays measuring binding to synthetic hydroxyapatite (SPR or solid-phase) require properly folded dimeric ALPL-Fc.
- pH-dependent activity: ALPL optimal pH is 9.0–9.5, but retains residual activity at physiological pH 7.4–7.8. Dual-pH screening (pH 7.4 and pH 9.0) is recommended to mimic pathological vs. normal environments.